


IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

**Claim 1 (Previously Amended).**

A compound of structural formula I:



or a pharmaceutically acceptable salt or an enantiomer thereof; wherein

n is 0, 1 or 2;

a-b represents CF=CH, CHFCH<sub>2</sub>, or CF<sub>2</sub>CH<sub>2</sub>;

R<sup>1</sup> is hydrogen, hydroxymethyl, or C<sub>1-3</sub> alkyl, wherein alkyl is unsubstituted or substituted with one to seven fluorine atoms;

R<sup>2</sup> is hydrogen or C<sub>1-4</sub> alkyl;

R<sup>3</sup> is selected from

(CH<sub>2</sub>)<sub>n</sub>-cycloheteroalkyl, and

(CH<sub>2</sub>)<sub>n</sub>-aryl, wherein aryl is selected from

- (1) phenyl,
- (2) naphthyl,
- (3) benzimidazolyl,
- (4) imidazopyridinyl,
- (5) benzofuranyl,
- (6) benzothiophenyl,
- (7) benzoxazolyl,
- (8) benzothiazolyl,
- (9) benzodihydrofuranyl,
- (10) 1,3-benzodioxolyl,
- (11) 2,3-dihydro-1,4-benzodioxinyl,
- (12) indolyl,


- (13) quinolyl,
- (14) isoquinolyl,
- (15) furanyl,
- (16) thienyl,
- (17) imidazolyl,
- (18) oxazolyl,
- (19) thiazolyl,
- (20) isoxazolyl,
- (21) isothiazolyl,
- (22) pyrazolyl,
- (23) pyrrolyl,
- (24) pyridyl,
- (25) pyrimidyl,
- (26) pyrazinyl,
- (27) thiadiazolyl,
- (28) oxadiazolyl,
- (29) triazolyl,
- (30) tetrazolyl, and
- (31) indanyl;

wherein the alkyl group or the cycloheteroalkyl group is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkoxy; the aryl group as defined in items (1) to (30) is unsubstituted or substituted with one to three groups independently selected from halogen, phenyl, C<sub>1-8</sub> alkyl, C<sub>3-8</sub> cycloalkyl, C<sub>3-8</sub> cycloheteroalkyl, phenyl-C<sub>1-6</sub> alkyl, amino-C<sub>0-6</sub> alkyl, C<sub>1-6</sub> alkylamino-C<sub>0-6</sub> alkyl, (C<sub>1-6</sub> alkyl)<sub>2</sub>amino-C<sub>0-6</sub> alkyl, phenyl-C<sub>0-6</sub> alkylamino-C<sub>0-6</sub> alkyl, (phenyl-C<sub>0-6</sub> alkyl)<sub>2</sub>amino-C<sub>0-6</sub> alkyl, C<sub>1-6</sub> alkylthio, phenyl-C<sub>0-6</sub> alkylthio, C<sub>1-6</sub> alkylsulfinyl, phenyl-C<sub>0-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyl, phenyl-C<sub>0-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkoxy-C<sub>0-6</sub> alkyl, phenyl-C<sub>0-6</sub> alkoxy-C<sub>0-6</sub> alkyl, hydroxycarbonyl-C<sub>0-6</sub> alkyl, C<sub>1-6</sub> alkoxycarbonyl-C<sub>0-6</sub> alkyl, phenyl-C<sub>0-6</sub> alkoxycarbonyl-C<sub>0-6</sub> alkyl, hydroxycarbonyl-C<sub>1-6</sub> alkyloxy, hydroxy-C<sub>0-6</sub> alkyl, cyano, nitro, perfluoro-C<sub>1-4</sub> alkyl, perfluoro-C<sub>1-4</sub> alkoxy, oxo, C<sub>1-6</sub> alkylcarbonyloxy, phenyl-C<sub>0-6</sub> alkylcarbonyloxy, C<sub>1-6</sub> alkylcarbonylamino, phenyl-C<sub>0-6</sub> alkylcarbonylamino, C<sub>1-6</sub> alkylsulfonylamino, phenyl-C<sub>0-6</sub> alkylsulfonylamino, C<sub>1-6</sub> alkoxycarbonylamino, phenyl-C<sub>0-6</sub> alkoxycarbonylamino, C<sub>1-6</sub> alkylaminocarbonylamino, phenyl-C<sub>0-6</sub> alkylaminocarbonylamino, (C<sub>1-6</sub> alkyl)<sub>2</sub> aminocarbonylamino, (phenyl-C<sub>0-6</sub> alkyl)<sub>2</sub> aminocarbonylamino, (C<sub>1-6</sub> alkyl)<sub>2</sub> aminocarbonyloxy, and (phenyl-C<sub>0-6</sub> alkyl)<sub>2</sub>

aminocarbonyloxy; and wherein any methylene (CH<sub>2</sub>) carbon atom in (CH<sub>2</sub>)<sub>n</sub> is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl; or two substituents when on the same methylene (CH<sub>2</sub>) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;  
or R<sup>2</sup> and R<sup>3</sup> together form a 5- or 6-membered saturated ring fused with a 5- or 6-membered aromatic ring system having 0, 1, or 2 heteroatoms selected from the N, O, and S.

**Claim 2 (Original).** The compound of Claim 1 wherein R<sup>1</sup> is hydrogen or methyl.

**Claim 3 (Presently amended).** A compound of structural formula I:



or a pharmaceutically acceptable salt or an enantiomer thereof; wherein  
n is 0, 1 or 2;

a-b represents CF=CH, CHFCH<sub>2</sub>, or CF<sub>2</sub>CH<sub>2</sub>;

R<sup>1</sup> is hydrogen, hydroxymethyl, or C<sub>1-3</sub> alkyl, wherein alkyl is unsubstituted or substituted with one to seven fluorine atoms;

R<sup>2</sup> is hydrogen or C<sub>1-4</sub> alkyl;

R<sup>3</sup> is selected from

(CH<sub>2</sub>)<sub>n</sub>-aryl, wherein aryl is selected from

- (1) phenyl,
- (2) naphthyl,
- (3) benzimidazolyl,
- (4) imidazopyridinyl,
- (45) benzofuranyl,
- (56) benzothiophenyl,
- (67) benzoxazolyl,

(~~78~~) benzothiazolyl,  
(~~89~~) benzodihydrofuranyl,  
(~~910~~) 1,3-benzodioxolyl,  
(~~1011~~) 2,3-dihydro-1,4-benzodioxinyl,  
(~~1112~~) indolyl,  
(~~1213~~) quinolyl,  
(~~1314~~) isoquinolyl,  
(~~1415~~) furanyl,  
(~~1516~~) thienyl,  
(~~1617~~) imidazolyl,  
(~~1718~~) oxazolyl,  
(~~1819~~) thiazolyl,  
(~~1920~~) isoxazolyl,  
(~~2021~~) isothiazolyl,  
(~~2122~~) pyrazolyl,  
(~~2223~~) pyrrolyl,  
(~~2324~~) pyridyl,  
(~~2425~~) pyrimidyl,  
(~~2526~~) pyrazinyl,  
(~~2627~~) thiadiazolyl,  
(~~2728~~) oxadiazolyl,  
(~~2829~~) triazolyl,  
(~~2930~~) tetrazolyl, and  
(~~3031~~) indanyl;

wherein the alkyl group or the cycloheteroalkyl group is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkoxy; the aryl group as defined in items (1) to (30) is unsubstituted or substituted with one to three groups independently selected from halogen, phenyl, C<sub>1-8</sub> alkyl, C<sub>3-8</sub> cycloalkyl, C<sub>3-8</sub> cycloheteroalkyl, phenyl-C<sub>1-6</sub> alkyl, amino-C<sub>0-6</sub> alkyl, C<sub>1-6</sub> alkylamino-C<sub>0-6</sub> alkyl, (C<sub>1-6</sub> alkyl)<sub>2</sub>amino-C<sub>0-6</sub> alkyl, phenyl-C<sub>0-6</sub> alkylamino-C<sub>0-6</sub> alkyl, (phenyl-C<sub>0-6</sub> alkyl)<sub>2</sub>amino-C<sub>0-6</sub> alkyl, C<sub>1-6</sub> alkylthio, phenyl-C<sub>0-6</sub> alkylthio, C<sub>1-6</sub> alkylsulfinyl, phenyl-C<sub>0-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkylsulfonyl, phenyl-C<sub>0-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkoxy-C<sub>0-6</sub> alkyl, phenyl-C<sub>0-6</sub> alkoxy-C<sub>0-6</sub> alkyl, hydroxycarbonyl-C<sub>0-6</sub> alkyl, C<sub>1-6</sub> alkoxycarbonyl-C<sub>0-6</sub> alkyl, phenyl-C<sub>0-6</sub> alkoxycarbonyl-C<sub>0-6</sub> alkyl, hydroxycarbonyl-C<sub>1-6</sub> alkyloxy, hydroxy-C<sub>0-6</sub> alkyl, cyano, nitro, perfluoro-

C<sub>1-4</sub> alkyl, perfluoro-C<sub>1-4</sub> alkoxy, oxo, C<sub>1-6</sub> alkylcarbonyloxy, phenyl-C<sub>0-6</sub> alkylcarbonyloxy, C<sub>1-6</sub> alkylcarbonylamino, phenyl-C<sub>0-6</sub> alkylcarbonylamino, C<sub>1-6</sub> alkylsulfonylamino, phenyl-C<sub>0-6</sub> alkylsulfonylamino, C<sub>1-6</sub> alkoxy carbonylamino, phenyl-C<sub>0-6</sub> alkoxy carbonylamino, C<sub>1-6</sub> alkylaminocarbonylamino, phenyl-C<sub>0-6</sub> alkylaminocarbonylamino, (C<sub>1-6</sub> alkyl)<sub>2</sub> aminocarbonylamino, (phenyl-C<sub>0-6</sub> alkyl)<sub>2</sub> aminocarbonylamino, (C<sub>1-6</sub> alkyl)<sub>2</sub> aminocarbonyloxy, and (phenyl-C<sub>0-6</sub> alkyl)<sub>2</sub> aminocarbonyloxy; and wherein any methylene (CH<sub>2</sub>) carbon atom in (CH<sub>2</sub>)<sub>n</sub> is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C<sub>1-4</sub> alkyl; or two substituents when on the same methylene (CH<sub>2</sub>) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group; or R<sup>2</sup> and R<sup>3</sup> together form a 5- or 6-membered saturated ring fused with a 5- or 6-membered aromatic ring system having 0, 1, or 2 heteroatoms selected from the N, O, and S.

**Claim 4 (Original).** The compound of Claim 3, wherein R<sup>1</sup> is hydrogen or methyl.

**Claim 5 (Original).** The compound of Claim 1 wherein a-b represents CF=CH.

**Claim 6 (Original).** The compound of Claim 1 wherein a-b represents CHFCH<sub>2</sub>.

**Claim 7 (Original).** The compound of Claim 1 wherein R<sup>2</sup> is hydrogen and R<sup>3</sup> is (CH<sub>2</sub>)<sub>n</sub>-aryl.

**Claim 8 (Original).** The compound of Claim 7 wherein n is 0 or 1.

**Claim 9 (Original).** The compound of Claim 1 wherein R<sup>1</sup> is methyl, a-b represents CF=CH, R<sup>2</sup> is hydrogen, and R<sup>3</sup> is (CH<sub>2</sub>)<sub>n</sub>-aryl.

**Claim 10 (Original).** The compound of Claim 9 wherein n is 0 or 1.

**Claim 11 (Original).** The compound of Claim 1 wherein R<sup>1</sup> is methyl, a-b represents CHFCH<sub>2</sub>, R<sup>2</sup> is hydrogen, and R<sup>3</sup> is (CH<sub>2</sub>)<sub>n</sub>-aryl.

**Claim 12 (Original).** The compound of Claim 11 wherein n is 0 or 1.

**Claim 13 (Original).** The compound of Claim 1 wherein R<sup>1</sup> is methyl, a-b represents CF=CH, R<sup>2</sup> is hydrogen, and R<sup>3</sup> is (CH<sub>2</sub>)<sub>n</sub>-cycloheteroalkyl.

**Claim 14 (Original).** The compound of Claim 13, wherein n is 0 or 1.

**Claim 15 (Original).** The compound of Claim 1 wherein R<sup>1</sup> is methyl, a-b represents CHFCH<sub>2</sub>, R<sup>2</sup> is hydrogen, and R<sup>3</sup> is (CH<sub>2</sub>)<sub>n</sub>-cycloheteroalkyl.

**Claim 16 (Original).** The compound of Claim 15, wherein n is 0 or 1.

**Claim 17 (Previously amended).** The compound of Claim 2 chosen from:  
N-(2-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(3-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(2-trifluoromethylphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(2-chlorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(4-methoxyphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(3-methoxyphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(2-methylphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(3-methylphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(2-fluorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(3-fluorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(4-fluorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(4-chloro-2-fluorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(2,4-difluorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-( $\alpha$ -methylphenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(phenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(4-chloro-2-trifluoromethylphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(5-methylpyridin-2-yl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(thiophen-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(thiophen-3-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(2-trifluoromethylphenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(benzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(1-methylbenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(1-methyl-5-trifluoromethylbenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(5-chlorobenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(5-methoxybenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(benzthiazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(thiazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(4-methylthiazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(thiazol-4-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(1-methylimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(tetrahydro-2H-pyran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(tetrahydro-2H-pyran-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(2,3-dihydro-1,4-benzodioxin-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(2,3-dihydro-1,4-benzodioxin-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(tetrahydrofuran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(tetrahydrofuran-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;

N-(2-fluorophenylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;

N-(2-trifluoromethylphenylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;

N-(3-methoxyphenyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;

N-(4-methoxyphenyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;

N-(2-trifluoromethylphenyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;

N-(2-chlorophenyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;

N-(2-fluorophenylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;

N-(benzimidazol-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;

N-(1-methylbenzimidazol-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -carboxamide;  
N-(thiazol-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -carboxamide;  
N-(furan-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -carboxamide; and  
N-(thiophen-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -carboxamide;  
pharmaceutically acceptable salts and enantiomers thereof.

**Claim 18 (Original).**

The compound of Claim 17 chosen from:

N-(2-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(3-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(5-chlorobenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(5-methoxybenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -  
carboxamide;  
N-(benzthiazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(tetrahydro-2H-pyran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -  
carboxamide;  
N-(tetrahydro-2H-pyran-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -  
carboxamide;  
N-(2,3-dihydro-1,4-benzodioxin-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -  
carboxamide;  
N-(2,3-dihydro-1,4-benzodioxin-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -  
carboxamide;  
N-(tetrahydrofuran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(tetrahydrofuran-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -  
carboxamide;  
N-(2-fluorophenylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -carboxamide;  
N-(thiazol-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -carboxamide;  
N-(furan-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -carboxamide; and  
N-(thiophen-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-17 $\beta$ -carboxamide;  
pharmaceutically acceptable salts and enantiomers thereof.

**Claim 19 (Original).**

The compound of Claim 18 chosen from:

N-(tetrahydro-2H-pyran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -  
carboxamide;

N-(tetrahydro-2H-pyran-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(2,3-dihydro-1,4-benzodioxin-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(2,3-dihydro-1,4-benzodioxin-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(tetrahydrofuran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(tetrahydrofuran-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(3H-imidazo[4,5-b]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
pharmaceutically acceptable salts and enantiomers thereof.

**Claim 20 (Original).** The compound of Claim 18 chosen from:  
N-(2-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(3-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(5-chlorobenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(5-methoxybenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(benzthiazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide;  
N-(2-fluorophenylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;  
N-(thiazol-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;  
N-(furan-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide; and  
N-(thiophen-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide;  
pharmaceutically acceptable salts and enantiomers thereof.

**Claim 21 (Previously Canceled).**

**Claim 22 (Previously Canceled).**

**Claim 23 (Previously Canceled).**

**Claim 24 (Previously Canceled).**

**Claim 25 (Previously Canceled).**

**Claim 26 (Previously Canceled).**

**Claim 27 (Previously Canceled).**

**Claim 28 (Previously Canceled).**

**Claim 29 (Previously Canceled).**

**Claim 30 (Previously Canceled).**

**Claim 31 (Previously Canceled).**

**Claim 32 (Previously Canceled).**

**Claim 33 (Previously Canceled).**

**Claim 34 (Previously Canceled).**

**Claim 35 (Previously Canceled).**

**Claim 36 (Previously Canceled).**

**Claim 37 (Previously Canceled).**

**Claim 38 (Previously Canceled).**

**Claim 39 (Previously Canceled).**

**Claim 40 (Previously Canceled).**

**Claim 41 (Previously Canceled).**

**Claim 42 (Newly Presented).**

A compound of Claim 18, chosen from:

N-(2,2,2-trifluoroethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide,  
N-(2-fluorophenylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide,  
N-(benzimidazol-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide,  
N-(3*H*-imidazo[4,5-*b*]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -  
carboxamide, pharmaceutically acceptable salts and enantiomers thereof.

**Claim 43 (Newly Presented).** A compound chosen from:  
N-(2,2,2-trifluoroethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -carboxamide,  
pharmaceutically acceptable salts and enantiomers thereof.


**Claim 44 (Newly Presented).** A compound chosen from:  
N-(2-fluorophenylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide,  
pharmaceutically acceptable salts and enantiomers thereof.

**Claim 45 (Newly Presented).** A compound chosen from:  
N-(benzimidazol-2-ylmethyl)-2 $\alpha$ -fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androstan-17 $\beta$ -carboxamide,  
pharmaceutically acceptable salts and enantiomers thereof.

**Claim 46 (Newly Presented).** A compound chosen from:  
N-(3*H*-imidazo[4,5-*b*]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -  
carboxamide, pharmaceutically acceptable salts and enantiomers thereof.

**Claim 47 (Newly Presented).** A compound  
N-(3*H*-imidazo[4,5-*b*]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 $\alpha$ -androst-1-en-17 $\beta$ -  
carboxamide.

**Claim 48 (Newly Presented).** A compound of structural formula:



pharmaceutically acceptable salts and enantiomers thereof.

**Claim 49 (Newly Presented).**

A compound of structural formula:

